Asthma Flashcards

1
Q

how does the WHO define asthma?

A

– Recurrent episodes
– Variability
– Reversibile airways inflammation
– Bronchial hyper-responsiveness to external
stimuli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the pathophysiology of the early phase of asthma?

A
  • Initiation of inflammatory cascade (early phase) – IgE
    antibodies released
  • IgE leads to activation of mast cells
  • Activation of mast cells lead to release of
    leukotrienes, cytokines, histamine smooth muscle
    constriction and inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the pathophysiology of the late phase asthma?

A

T-cells, macrophages, eosinophils recruit ->
inflammation and bronchoconstriction (late phase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the main causes/ triggers of asthma?

A

– Genetic links - not absolute
– House dust mite
– Animal allergens- e.g. cats
– Pollens e.g. grass, trees
– Infections - particularly viral
– Occupational agents in workplace
– Drugs
– Passive / current smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how do you confirm diagnosis of high probability asthma?

A

– Six week treatment trial of inhaled corticosteroids and SABA
– Assess response objectively (done as part of SCA)
* Baseline needed
* Assess patient status using a validated symptom questionnaire
(asthma control questionnaire)
* Perform objective lung function tests (spirometry OR peak
expiratory flow)
Improvements in symptoms and objective tests following
treatment trials strongly indicate asthma. Lack of improvements
suggest alternative diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what would a normal patients spirometry reading show?

A
  • High forced vital capacity (FVC)
  • High forced expiratory volume in one second (FEV1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what would an obstructive patients spirometry reading show?

A
  • Low forced vital capacity (FVC)
  • Low forced expiratory volume in one second (FEV1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what increases the probability of asthma in spirometry?

A

– Obstructive: FEV1/FVC <0.7
– Positive result: improvement in FEV1 of ≥ 12% with an increase in volume of 200ml
– Improvement in FEV1 of ≥ 400ml – strongly suggests asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is a peak flow?

A
  • Provides estimate in variability of
    airflow based on level of inflammation
    in lungs – different to spirometry!
  • Measures force an individual can
    breath out with
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how does the peak flow meter work?

A
  • Patients have a baseline that is normal
    for them but there are expected values
    based on height, weight, age.
    – More inflammation on lungs –
    lower scores compared to baseline
    – Less inflammation on lungs –
    higher / normal scores compared
    to baseline
  • We look for variability in readings over
    a 2 week period to gauge diagnosis /
    control of asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how do you preform a peak flow meter?

A

– Deep breath in
– Hold breath for two seconds
– Rapidly breathe out
– Record value
– Do this three times morning and night and record the best from each
Repeat this twice daily for two weeks
* Take an average of all “best” readings from daytime and evening
* Take the highest and the lowest readings and calculate express
these as a percentage of the average. A 20% difference between
these values strongly suggests asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is complete control defined as?

A

– No daytime symptoms
– No night time awakening due to asthma
– No need for rescue medication
– No asthma attacks
– No limitations on activity including exercise
– Normal lung function
– Minimal side-effects from medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the BTS approach to asthma?

A
  • Start at the level most appropriate to initial severity
    – For most individuals this is SABA PRN for relief of
    symptoms and ICS BD for prevention of symptoms
  • Overall aim: Achieve early control reduce risk of
    acute attacks and hospitalisation
  • Maintain control by:
    – Increasing treatment
    – Decreasing treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the drug treatment available for asthma?

A
  • Relievers
    – Bronchodilators: relax smooth muscle in walls of airways
    – Salbutamol, terbutaline – SABAs (short acting beta agonists)
  • Preventers
    – anti inflammatory drugs which reduce inflammation in the airways e.g. corticosteroids, leukotriene receptor
    antagonists
    – Bronchodilators: long acting beta agonists to provide
    longer lasting relaxation of smooth muscles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

when should you step up therapies?

A

– Asthma attack in the last 2 years
– Using inhaled SAB2A 3 times per week
or more
– Symptomatic 3 times per week or more
– Waking 1 night per week
– Asthma affecting daily activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

when should you decrease therapy?

A

–When good control is established –
consider decreasing therapy
–ICS: stable patients, consider
reducing dose by 25 – 50% every 3
months

17
Q

what are the important points relating to SABA?

A

– Little or no use is classified as GOOD asthma control.
– Regular use suggests possible poor control - we should be aiming to control symptoms with
preventer inhalers not rely on relievers to manage symptoms when present. Evidence
suggests over-reliance of SABA associated with increased mortality.
– If a MART regime initiated, no need for SABA (see later slides)

18
Q

what are the important points relating to ICS?

A

– Should be prescribed at ALL stages of asthma management.
– Counselling essential on adherence and minimisation of side effect risk.
– Growth retardation - rare and mostly occurs in children up to 1 year old.
– Brand prescribing – beclomethasone bioavailability differences (Clenil versus QVAR)
– Potencies – BDP:BUD (1:1). FLU:BPD (1:0.5)

19
Q

what ae the important points relating to LABA?

A

– Never to be prescribed without ICS – increased mortality
– Combination inhalers: Safety, adherence, no difference in efficacy

20
Q

what are some examples of combination inhalers?

A

– Fostair (Formoterol / beclomethasone)
– DuoResp (formoterol / budesonide)
– Seretide, sirdupla, sereflo (salmeterol / fluticasone)
– Relvar (Vilanterol / fluticasone)

21
Q

what is theophylline?

A

– Modified release
– Extensive hepatic metabolism and narrow therapeutic index (interactions)
* Inhibitors, inducers, smoking, heart failure
– Monitoring – 5 days after starting, 3 days after dose change taken 4-6 hours after
a dose (10-20mg/L target)

22
Q

what is a MART regimes?

A

MART: Maintenance and Reliever Therapy
– Alternative approach to fixed dose initial add on therapy (LABA/ICS)
* ONE inhaler is used as both reliever (PRN use) and preventer (BD use)

23
Q

what does a MART contain? what was ge reason for this?

A

MART regimes still contain a LABA and ICS but the LABA must be one which is rapid acting so that it can act as a reliever therapy. E.G. formoterol

24
Q

what are the requirements to prescribe a MART regimen?

A

– 18+
– Continued poor control despite taking regular preventative therapies
– When one inhaler is preferred over separate preventer and reliever

25
Q

what advice should you give to a patient on MART regime?

A

– A maintenance dose in the morning and evening should continually be
used
– If you have symptoms throughout the day, you can use extra puffs of
your inhaler (reliever doses).
– For example: Fostair 100/6mcg 1p BD. Use additional puffs PRN up to a
maximum of six extra doses per day (max 8 puffs per day)

26
Q

What is the benefit of MART regimes?

A

– Keeps inflammation in airways to a minimum
– Gives ongoing relief of symptoms such as breathlessness or chest
tightness
– Acts quickly to manage symptoms and reduce risk of developing an
asthma attack and therefore reduces risk of hospital admission
– As patients use more extra reliever doses, the requirement will reduce
with time due to the extra anti-inflammatory effects of the ICS and
therefore provides longer term control of asthma

27
Q

what are the common therapeutic problems with asthma?

A
  • Under diagnosed
  • Failing to avoid / reduce exposure to allergens
  • Lack of patient knowledge about condition and its
    management
  • When to start ICS Tx
  • Taking ICS “prn”
  • Missing signs of deteriorating asthma control
  • Poor technique – poor compliance
28
Q

what should you check on asthma review?

A

Adherence – is the patient taking their preventative
medications correctly
* Inhaler technique – are they using their inhalers properly
(can they SHOW you)
* Symptoms: Daytime, night time, activities
– SABA use as a result? >3x/week?
* Asthma control questionnaire
* Peak expiratory flow readings (variability)
* Triggers / smoking status
* Does the patient have a PAAP? (See later)

29
Q

what are the different type of devices available?

A
  • pMDI (standard or easi-breathe)

– Salbutamol evohaler, salbutamol breath-actuated
– Fostair evohaler (formoterol/beclomethasone), Seretide evohaler
(salmeterol/fluticasone)

  • Soft mist (Respimat)
    – Spiriva Respimat (tiotropium)
  • Dry powder inhalers:
    – Turbohaler – Symbicort (formoterol/budesonide), Pulmicort (budesonide)
    – Breath actuated – DuoResp (formoterol/budesonide)
    – NEXThaler – Fostair (formoterol/beclomethasone)
    – Accuhaler – Seretide (salmeterol/fluticasone)
    – Ellipta – Incruse (umeclidinium)
    – Breezehaler – Seebri (glycopyrrinium)
    – Genuair – Eklira (aclidinium)
30
Q

what is acute asthma?

A

– Deteriorating symptoms over hours/days
– Increasing breathlessness, wheezing, coughing, tightness
– Difficulty talking in sentences
– Tachycardia, tachypnoea
– Reduced PEFR
– Reduced oxygen saturations

31
Q

how is moderate asthma classified?

A

spo2>92%
normal speech
RR <25
pulse<110

32
Q

how is acute severe asthma classified?

A

spo2>92%
cant complete sentences
RR >25
pulse>110

33
Q

how is life-threatening asthma classified?

A

spo2<92%
silent chest, cyanosis or poor respiratory effect
arrhythmia or hypo
exhaustion, alt consciousness

34
Q

what supported management is there?

A
  • Education
    – Disease
    – Symptom recognition + management (PAAP)
    – Review
    – Compliance/Inhaler technique
35
Q

what are supported self-management? non-pharmacological?

A
  • Non-pharmacological management
    – Avoid known allergens and triggers
  • Difficult, expensive, time consuming
    – Stop smoking, exposure to passive
    smoking
    – Breathing exercises
    – Ideal body weight